These success, along with a previous report displaying that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like actions in mice,2 aid the idea of targeting ACKR3 as a unique way to modulate the opioid program, which could open new therapeutic avenues for opioid-connected Conditions.